The classification can influence the therapeutic strategy, given that patients with type 1 VWD and cellular stores of VWF can be treated with an agent inducing VWF endothelial release (22), whilst patients with complete lack or dysfunction may require replacement therapy with plasma products. Here, VWF is linked to von Willebrand disease 1.